an increased frequency of T cells expressing the co-inhibitory receptors KLRG1 and TIGIT was detected. Importantly, the latter signature resembles the CD8 + T-cell signature associated with a ...

Another TIGIT trial failure has been abandoned ... with Daiichi Sankyo – as well as MK-6070, a DLL3-targeting T-cell engager acquired as part of its takeover of Harpoon Therapeutics which ...

drugs targeting TIGIT had become sought-after assets in the pharma industry, on the promise that they may inhibit anti-tumour responses that down-regulate the activity of T-cells and provide an ...

The anti-TIGIT therapy, vibostolimab, plus Keytruda and chemotherapy did not improve overall survival versus Tecentriq plus ...